SPY336.83-0.61 -0.18%
DIA279.42-0.62 -0.22%
IXIC11,042.50+30.27 0.27%

Cyclacel Pharmaceuticals Q3 EPS $(0.11) Beats $(0.16) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 38.89 percent increase over losses of $(0.18) per

Benzinga · -

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 38.89 percent increase over losses of $(0.18) per share from the same period last year.